Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by DJDawgon Feb 19, 2022 7:31pm
443 Views
Post# 34445546

RE:RE:RE:RE:Upcoming patient data

RE:RE:RE:RE:Upcoming patient data
Another interesting thing about the above graph of durable response (bcg+n-803) is that they hit 55% at 18 months but to my eyes it drops off another few steps so by 27 months it is around 25%. For these kind of graphs you get used to them leveling off as everyone who is in true remission stays that way. To have it keep dropping off makes me think that the CR isn't really a CR in a cure sense. If it were a "complete" response it wouldn't be coming back so much. I know that CR is defined by cytology and scope imaging but if I had bladder cancer, I wouldn't feel cured if you told me, at 18 m, that there was only a 50% chance of me going further as a CR. TLD-1433 on the other hand, one treatment for some and years of no recurrence (consider the 2 phase 1b patients that are still CR after one treatment way back).

So yes, impressive response but I have a hard time thinking of the response as durabe if it keeps falling off even after 24months. IMO
<< Previous
Bullboard Posts
Next >>